To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program Lead for their Early Pipeline Programs. To unlock the potential of next-generation human enzymes, Aeglea requires exceptional individuals who bring tremendous skill and talent with their experience. With 25+ years of experience in executive search, The Chase Group was able to utilize their vast network of life science professionals to identify the successful candidate. Reporting to the Chief Medical Officer, this respected and versatile leader is responsible for shaping the program strategy and generating data from clinical development activities. The Chase Group is honored to partner with Aeglea and support their dedication and passion to improve the lives of patients with unmet medical needs.